Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Mai 2024 - 10:00PM
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology
company leveraging its core competencies in immune cell modulation
and protein engineering to develop novel, investigational
engineered cytokine therapies designed to address areas of unmet
need for patients with a variety of cancers, today announced that
on May 1, the Company granted to three newly hired employees (i)
non-statutory stock options to purchase an aggregate of 20,150
ordinary shares of the Company and (ii) restricted stock units with
respect to an aggregate of 10,850 ordinary shares of the Company,
pursuant to the Company’s 2024 Inducement Stock Option and
Incentive Plan, each as an inducement material to the new employees
entering into employment with the Company in accordance with Nasdaq
Listing Rule 5635(c)(4).
The stock options have an exercise price of
$3.78 per share, which is equal to the closing price per share of
the Company’s ordinary shares as reported by Nasdaq on May 1, 2024.
The options have a ten-year term and vest over four years, with 25%
of the original number of shares vesting on the first anniversary
of the grant date and 6.25% of the shares underlying the options
vesting quarterly thereafter, subject to such employee’s continued
service with the Company through the applicable vesting dates. Each
of the stock options is subject to the terms and conditions of a
stock option award agreement covering the grant and the Company’s
2024 Inducement Stock Option and Incentive Plan. The restricted
stock units vest over four years, 25% per year on the anniversary
of the grant date, subject to such employee’s continued service
with the Company through the applicable vesting dates. Each of the
restricted stock units is subject to the terms and conditions of a
restricted stock award agreement covering the grant and the
Company’s 2024 Inducement Stock Option and Incentive Plan.
About Mural OncologyMural
Oncology is leveraging its novel protein engineering platform to
develop cytokine-based immunotherapies for the treatment of cancer.
By combining our expertise in cytokine biology and immune cell
modulation and our protein engineering platform, we are developing
medicines to deliver meaningful and clinical benefits to people
living with cancer. Our mission is to broaden the potential
and reach of cytokine-based immunotherapies to improve the lives of
patients. Our lead candidate, nemvaleukin, is currently in
potentially registrational trials in mucosal melanoma and
platinum-resistant ovarian cancer. Mural Oncology has its
registered office in Dublin, Ireland, and its primary facilities in
Waltham, Mass. For more information, visit Mural Oncology’s website
at www.muraloncology.com and follow us on LinkedIn and X.
Contacts
Investors:David Borah,
CFAdavid.borah@muraloncology.com 781-614-0060
Media:Katie
Sullivankatie.sullivan@muraloncology.com781-614-0034
Mural Oncology (NASDAQ:MURA)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Mural Oncology (NASDAQ:MURA)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024